#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Follicular lymphoma stage I Loss of consciousness Neuroendocrine tumour Cystic fibrosis gastrointestinal disease Advanced systemic mastocytosis Methylmalonic acidaemia Ependymoma Uveitis Splenic marginal zone lymphoma Congenital hypotransferrinaemia Osteosarcoma Pyoderma gangrenosum Acute myeloid leukaemia (in remission) Neurodegenerative disorder Canavan disease More trials…

    Learn about Rare Diseases

    Hereditary optic atrophy Retinitis pigmentosa – Diagnostics Shprintzen-Goldberg syndrome Cerebral arteriovenous malformation haemorrhagic – Treatment Rhabdoid tumour – Trials in Disease Gaucher’s disease type I – Basic Information Usher’s syndrome – Basic Information Leiomyosarcoma recurrent – Life with Disease Mucopolysaccharidosis – Life with Disease Medulloblastoma – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    NAVENIBART Tetracaine Hydrochloride Triamcinolone Hexacetonide Linperlisib Dexamethasone Sodium Phosphate Poa Pratensis Pollen Extract Busulfan Sodium Ascorbate GSK4524101A Tezacaftor Tremelimumab Dazukibart Maridebart Cafraglutide Etelcalcetide Streptococcus Agalactiae Amikacin Imlifidase Alirocumab GSKVX000000030825 Ecopipam Hydrochloride More therapies…

    Learn about Your Condition

    Thymoma Gaucher's disease type I Colorectal cancer stage II Round cell liposarcoma Hypotonia Hysterectomy Craniosynostosis Postoperative delirium Lymphocytic leukaemia Pleomorphic leiomyosarcoma Pyrexia Immune-mediated renal disorder Osteomyelitis Leiomyosarcoma metastatic Albright's disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Uniwersytecki Szpital Kliniczny W Bialymstoku

Uniwersytecki Szpital Kliniczny W Bialymstoku

Zurawia 14, Bialystok, 15-540, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • A study testing xanomeline tartrate and trospium chloride added to current treatment for adults with bipolar I disorder experiencing mania

    Recruiting

    3 1
    Investigated Diseases:
    • Bipolar I disorder
    Investigated Drugs:
    • Trospium Chloride
    • Xanomeline Tartrate
    Bulgaria Denmark France Italy Poland Romania

  • A Study of JNJ-78278343 Compared to Placebo for Patients with Advanced Prostate Cancer That No Longer Responds to Hormone Treatment

    Recruiting

    3 1
    Belgium France Germany Italy The Netherlands Poland +1

  • Study of IMVT-1402 Treatment for Adults with Graves’ Disease

    Recruiting

    2 1
    Investigated Drugs:
    • IMEROPRUBART
    Bulgaria Czechia Germany Greece Italy Latvia +3

  • Study comparing high-dose and low-dose aspirin with prasugrel and aspirin combination in patients after coronary artery bypass grafting surgery

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic coronary syndrome
    • Coronary artery disease
    Investigated Drugs:
    • Acetylsalicylic Acid
    • Prasugrel
    Poland

  • Long-term safety study of trospium chloride and xanomeline tartrate combination (KarXT) for treatment of manic episodes in adults with Bipolar I Disorder

    Recruiting

    3 1 1
    Investigated Drugs:
    • Trospium Chloride
    • Xanomeline Tartrate
    Bulgaria Croatia Denmark France Hungary Italy +5

  • Study of trospium chloride and xanomeline tartrate (KarXT) for treatment of manic episodes in adults with bipolar I disorder

    Recruiting

    3 1 1
    Investigated Diseases:
    • Bipolar I disorder
    Investigated Drugs:
    • Trospium Chloride
    • Xanomeline Tartrate
    Bulgaria Hungary Poland

  • Study of evenamide as add-on treatment for patients with treatment-resistant schizophrenia not adequately controlled by current antipsychotic medications

    Recruiting

    3 1
    Bulgaria Croatia Czechia France Germany Hungary +3

  • Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Hypertension
    • Type 2 diabetes mellitus
    • Cardiovascular disorder
    Investigated Drugs:
    • Bi 690517
    • Empagliflozin
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Long-term safety and effectiveness study of CYB003 (deupsilocin besilate) with optional additional doses for people with Major Depressive Disorder

    Recruiting

    3 1 1
    Czechia Germany Greece Ireland Poland

  • Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

    Recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    Investigated Drugs:
    • Maridebart Cafraglutide
    Austria Belgium Bulgaria Czechia Denmark Finland +12
Previous Page
1 2 3 4 5 … 16
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!